JPMorgan Chase & Co. Boosts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

JPMorgan Chase & Co. raised its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 166.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,043,441 shares of the company's stock after purchasing an additional 651,481 shares during the quarter. JPMorgan Chase & Co. owned 0.70% of Xeris Biopharma worth $3,537,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. R Squared Ltd purchased a new stake in Xeris Biopharma in the 4th quarter valued at about $42,000. Cibc World Markets Corp bought a new stake in Xeris Biopharma during the fourth quarter worth $44,000. Raymond James Financial Inc. purchased a new position in Xeris Biopharma in the fourth quarter worth $45,000. Virtu Financial LLC bought a new position in Xeris Biopharma in the 4th quarter valued at $58,000. Finally, Sunpointe LLC purchased a new stake in shares of Xeris Biopharma during the 4th quarter valued at $71,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Price Performance

Shares of XERS traded down $0.03 during trading hours on Friday, hitting $4.26. The company's stock had a trading volume of 634,076 shares, compared to its average volume of 1,867,956. The business has a 50 day simple moving average of $4.49 and a two-hundred day simple moving average of $3.73. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.69 and a 52-week high of $6.07. The company has a market cap of $655.01 million, a price-to-earnings ratio of -9.46 and a beta of 1.37.

Insider Buying and Selling

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. The trade was a 2.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.56% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Leerink Partners boosted their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, March 7th. Jefferies Financial Group restated a "buy" rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Craig Hallum upped their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research note on Friday, March 7th. Finally, Piper Sandler reissued a "neutral" rating and set a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $6.10.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.